Posted by Michael Wonder on 05 Nov 2020
Skin cancer drug not cost effective for routine NHS use
5 November 2020 - A consultation on the draft recommendations has now begun until Tuesday 24 November 2020.
NICE has today started a consultation on draft guidance which does not recommend the routine use of nivolumab (Opdivo; Bristol-Myers Squibb) as an option after surgery for some people with melanoma.
